SCHEMBL25565174

SCHEMBL25565174

Nc1ncnc2c1ncn2[C@H]1C[C@H](F)[C@@H](COP(=O)(O)OP(=O)(O)O)O1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.66
▸ P2RX3 P56373 6/20 0.65
▸ P2RX1 P51575 4/20 0.65
▸ P2RX2 Q9UBL9 2/20 0.65
▸ P2RX4 Q99571 5/20 0.62
▸ P2RY1 P47900 4/20 0.62
▸ P2RY2 P41231 2/20 0.62
▸ SRC P12931 1/20 0.62
▸ ALDH1A1 P00352 1/20 0.62
▸ SMN1; SMN2 Q16637 1/20 0.62
▸ ENPP1 P22413 2/20 0.60
▸ RNASEL Q05823 1/20 0.60
▸ MACROD2 A1Z1Q3 1/20 0.58
▸ SIRT6 Q8N6T7 1/20 0.58
▸ MACROD1 Q9BQ69 1/20 0.58
▸ TRPM2 O94759 1/20 0.58
▸ P2RX7 Q99572 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31069787 0.99 P2RX3 (0.66) POLBP2RX3P2RX1P2RX2P2RX4
SCHEMBL12932298 0.99 P2RX3 (0.66) POLBP2RX3P2RX1P2RX2P2RX4
SCHEMBL1062774 0.99 P2RX3 (0.66) POLBP2RX3P2RX1P2RX2P2RX4
SCHEMBL8616900 0.92 P2RY1 (0.66) POLBP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL21132954 0.90 POLB (0.62) POLBP2RX3P2RX1P2RX2P2RX4
SCHEMBL29352481 0.90 POLB (0.81) POLBP2RX3P2RX1P2RX2P2RX4
SCHEMBL2508784 0.90 POLB (0.81) POLBP2RX3P2RX1P2RX2P2RX4
SCHEMBL77641 0.90 POLB (0.81) POLBP2RX3P2RX1P2RX2P2RX4
SCHEMBL31211719 0.90 POLB (0.81) POLBP2RX3P2RX1P2RX2P2RX4
SCHEMBL703733 0.89 POLB (0.80) POLBP2RX3P2RX1P2RX2P2RX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023086557-A1 NUCLEOSIDES FOR THE TREATMENT OF DNA VIRUS INFECTIONS EMORY UNIVERSITY (US) 2023-05-19 — — WO disclosed
Send feedback